A 27-year-old female patient who came for branchial cyst excision was found to have cyanosis and a saturation gap during preanesthetic check-up and hence she was referred to haematology for further workup. She had a Hb of 9 gm% with all other baseline tests as normal. Blood samples were sent for methaemoglobin estimation and related work up to the National Institute of Immunohematology (NIIH) Mumbai. She was diagnosed as a case of Methemoglobinemia with a methaemoglobin level of 68.7% with NADH cytochrome B5 reductase activity of 10.82 IU/g Hb. The drug of choice for treatment is Methylene blue and hence G6PD deficiency had to be ruled out prior to initiating therapy. She was found to have a concurrent existence of G6PD deficiency. The blood sample was further sent to NIIH for genetic confirmation. We avoided methylene blue and other precipitating factors that could trigger a haemolysis. She was further consulted by the Patient blood management team to optimize her erythropoiesis and avoid unnecessary transfusions. Anaesthetic consultation and planning were done to avoid drugs that could induce haemolysis. She was started on Vitamin C, Niacin, hematinic and advised to follow up after a month. She was symptomatically better. Cyanosis had reduced, and Hb improved to 12 gm%. She was taken up for surgery with all precautions. The surgery and the post-operative period were uneventful. She was discharged on postoperative day 4 with an advice to continue Vitamin C & Niacin and to follow-up in Haematology OPD after a month.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528542PMC
http://dx.doi.org/10.4103/ajts.ajts_152_20DOI Listing

Publication Analysis

Top Keywords

g6pd deficiency
12
branchial cyst
8
methylene blue
8
vitamin niacin
8
successful management
4
management methemoglobinemia
4
methemoglobinemia g6pd
4
deficiency patient
4
patient posted
4
posted surgical
4

Similar Publications

Health disparities in diabetes treatment: The challenge of G6PD deficiency.

Diabetes Res Clin Pract

December 2024

Leumit Research Institute, Leumit Health Services, Tel-Aviv, Israel; Adelson School of Medicine, Ariel University, Ariel, Israel.

Aims: To assess the impact of Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an enzymatic deficiency prevalent in individuals of African or Asian descent, on Hemoglobin A1c (HbA1c) levels, diabetes medication purchases, and the cumulative incidence of diabetes related complications.

Methods: A large cohort study was conducted within a national health organization, comparing 3,913 G6PD-deficient patients to a matched control group without G6PD deficiency over two decades. The main measures and outcomes were the HbA1c levels, patterns of diabetes medication purchases, and the incidence of severe diabetes-related complications.

View Article and Find Full Text PDF

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an enzymopathy that affects approximately 500 million people worldwide. A great number of mutations in the gene have been described. However, three class A G6PD variants known as G6PD Tomah (C385R), G6PD Kangnam (C385G), and G6PD Madrid (C385W) have been reported to be clinically important due to their associations with severe clinical manifestations such as hemolytic anemia.

View Article and Find Full Text PDF

Tumor lysis syndrome (TLS) is a critical oncologic emergency characterized by metabolic disturbances resulting from rapid cancer cell lysis. Rasburicase, a recombinant urate oxidase, is the primary treatment for hyperuricemia in TLS but poses a risk for methemoglobinemia in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. We present the case of a 59-year-old male with diffuse large B-cell lymphoma (DLBCL) who developed spontaneous TLS.

View Article and Find Full Text PDF

Rising epidemiological trends in prevalence and mortality of mpox: Global insights and analysis.

Saudi Med J

December 2024

From the College of Medicine (MOS Meo, MZS Meo, Khan), Alfaisal University; from the Department of Family Medicine (Butt) and Department of Physiology (S. Meo), College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.

Objectives: To explore the global epidemiological trends in the prevalence and mortality due to mpox in various regions worldwide.

Methods: In this cross-sectional study the data about mpox outbreak were recorded by the "World Health Organization, Centers for Disease Control and Prevention, and GSAID" from August 2023 to August 2024, analyzing the epidemiological trends from different countries worldwide.

Results: The total number of mpox cases has reached 99,518 (95,196 cases from 115 countries that have not historically reported mpox; and 4,322 cases from 07 states that have traditionally reported mpox), from a total of 122 countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!